Ionis Pharmaceuticals listed on Nasdaq, partnered with AstraZeneca on a trial, and was investigated for potential securities law violations.

The entities involved

• Ionis Pharmaceuticals →

  American pharmaceutical company

  • GSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.Sat 18:16
• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52
• Nasdaq →

  American fully electronic stock exchange

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28

Related events

• Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.Aug 28
• Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.Aug 5
• Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.Wed 10:43
• Pro-Dex, Inc. was listed on the Nasdaq stock exchange and disclosed a transaction via a legal filing with the SEC.Sep 13
• Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.Sep 11